




ACTAS Derma-Sifiliográficas

Full English text available at
www.actasdermo.org



ADVANCES IN DERMATOLOGY

Kidney Disease and Psoriasis. A New Comorbidity?☆



E. González-Parra,^a E. Daudén,^b J.M. Carrascosa,^c A. Olveira,^d R. Botella,^f
C. Bonanad,^g R. Rivera^{e,*}, for the Systemic Inflammation in Psoriasis Working Group

^a Servicio de Nefrología, Hospital La Fundación Jiménez Díaz, Madrid, Spain

^b Servicio de Dermatología, Hospital La Princesa, Madrid, Spain

^c Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain

^d Servicio de Aparato Digestivo, Hospital La Paz, Madrid, Spain

^e Servicio de Dermatología, Hospital 12 de Octubre, Madrid, Spain

^f Servicio de Dermatología, Hospital Universitario La Fe, Valencia, Spain

^g Servicio de Cardiología, Hospital Clínico Universitario, Valencia, Spain

Received 18 April 2016; accepted 29 May 2016

Available online 22 October 2016

KEYWORDS

Psoriasis;
Kidney disease;
Comorbidity

Abstract Psoriasis is a chronic inflammatory disease that has been associated with cardiovascular and metabolic comorbidities, particularly in young patients and patients with more severe forms of the disease. Recent studies have also linked psoriasis to kidney disease, and this would seem only logical, as the kidney is both a target of classic cardiovascular risk factors and susceptible to the toxic effects of some of the traditional drugs used to control psoriasis.

In this article, we would like to draw readers' attention to this recently described comorbidity and stress the importance of early detection, as once chronic kidney disease develops, it cannot be reversed. When evaluating patients with psoriasis, particularly when they are candidates for systemic therapy, we believe it is important to order laboratory tests including glomerular filtration rate and a simple urine test to screen for albuminuria (albumin/creatinine ratio).

© 2016 Elsevier España, S.L.U. and AEDV. All rights reserved.

☆ Please cite this article as: González-Parra E, Daudén E, Carrascosa JM, Olveira A, Botella R, Bonanad C, et al. Enfermedad renal y psoriasis. ¿Una nueva comorbilidad? Actas Dermosifiliogr. 2016;107:823–829.

* Corresponding author.

E-mail address: rriveradiaz@hotmail.com (R. Rivera).

PALABRAS CLAVE

Psoriasis;
Enfermedad renal;
Comorbilidad

Enfermedad renal y psoriasis. ¿Una nueva comorbilidad?

Resumen La psoriasis es un proceso inflamatorio crónico que se ha asociado con comorbilidades cardiovasculares y metabólicas, especialmente las formas más graves y en pacientes jóvenes. Estudios recientes relacionan también la psoriasis con enfermedad renal, y parece lógico que sea así porque, por un lado, el riñón es un órgano diana de los factores de riesgo cardiovascular clásicos, y además, algunos de los tratamientos clásicos empleados para controlar la psoriasis tienen toxicidad renal. Con este artículo queremos hacer una llamada de atención sobre esta comorbilidad recientemente descrita; es fundamental su detección precoz porque una vez instaurada, la enfermedad renal crónica es irreversible. Consideramos importante que en el estudio basal de todo paciente con psoriasis, especialmente aquellos que van a recibir terapia sistémica, se analice la función renal con una analítica de sangre con filtrado glomerular y un análisis sencillo de orina para estudiar la albuminuria (relación albúmina/creatinina).

© 2016 Elsevier España, S.L.U. y AEDV. Todos los derechos reservados.

Introduction

Psoriasis is a chronic and recurrent inflammatory skin disease affecting between 0.1% and 2.9% of the population worldwide,^{1,2} with an estimated prevalence in Spain of 2.3%.³ Disease severity is variable and the condition is not confined to the skin, but can also affect the patient's joints. In one epidemiological survey in Spain and Portugal, psoriatic arthritis was confirmed in 12.8% of patients.⁴ Psoriasis can also have other systemic manifestations.⁵ Associations have been observed between psoriasis and many other disorders, including diabetes mellitus, obesity, heart disease, hypertension, Crohn disease, cancer, and depression. In recent years, the systemic dimension of psoriasis has generated considerable interest, with a focus on prevention, early diagnosis and treatment as well as on the implications of these comorbidities on the overall management of psoriatic disease.⁶

Association Between Psoriasis and Systemic Disease. Cardiovascular Risk Factors

It is possible that the association observed between psoriasis and other diseases may be due to the underlying inflammatory process that affects these patients. The most common comorbidities are obesity,⁷ hypertension, hyperlipidemia,⁸ and diabetes,⁹ all of which are cardiovascular (CV) risk factors. The increased CV risk in patients with psoriasis is the result of multiple factors:

1. The presence of a systemic inflammatory process that gives rise to an increase in inflammatory disorders, such as atherosclerosis.¹⁰
2. The higher prevalence in this population of unhealthy behaviors, including excessive alcohol consumption, smoking, and a sedentary lifestyle.¹¹
3. An increase in CV risk factors such as hypertension, diabetes, and dyslipidemia.⁸
4. Treatment with drugs such as ciclosporin (CsA) and acitretin, which can increase CV risk. CsA can increase blood pressure and cause hyperlipidemia¹² and acitretin

can alter the patient's lipid profile, leading to increased triglyceride and cholesterol levels.¹³

Most of the evidence linking psoriasis with systemic diseases comes from observational epidemiological studies. As a result, some authors have expressed doubts about the hypothesis that psoriasis is a systemic disease and have questioned the existence of a common mechanism linking psoriasis with the observed comorbidities.¹¹ The fact that several diseases are associated does not necessarily imply that a common mechanism exists.¹⁴ Several authors have highlighted the association between psoriasis and atherosclerosis¹⁰ and have found psoriasis to be an independent risk factor for CV disease (myocardial infarction), particularly in young patients with severe psoriasis.¹⁵ Other authors have found no such association, but those studies did not include young patients and, in most cases, the patients included did not require systemic treatment or phototherapy to control their psoriasis.¹⁶

When the mechanisms that cause the systemic and renal disorders are analyzed, the systemic inflammatory process appears to play a fundamental role. Inflammation causes an increase in insulin resistance, and levels of the cytokines present—such as adiponectin—correlate with diastolic blood pressure and low-density lipoprotein.¹⁷ The inflammation, in conjunction with the infection, provokes multiple alterations in lipid and lipoprotein metabolism, many of which are proatherogenic, increasing triglyceride and total cholesterol levels.¹⁸ Numerous studies have compared serum lipid levels in patients with psoriasis and controls. The results vary considerably from study to study owing to differences between study populations in disease severity and in the presence of comorbidities known to affect lipid metabolism, such as obesity. A general tendency has been observed towards increased serum triglyceride levels and decreased levels of high density lipoproteins in patients with psoriasis.^{19–21}

The presence of psoriatic arthritis also increases the risk of CV disease, which suggests that the presence of a systemic inflammatory process may, by itself, be a CV risk factor.²² In severe cases, an increase has been observed in inflammatory markers, such as C-reactive protein and

Table 1 Hazard Ratio for Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD) in Patients With Psoriasis in Two Cohort Studies.

Cohort Study	All Psoriasis	Severe Psoriasis
<i>Adjusted hazard ratio (95% CI) for CKD^a</i>		
Wan, et al. ²⁴	1.05 (1.02-1.07)	1.93 (1.79-2.08)
Chi et al. ²⁵	1.09 (0.94-1.27)	1.87 (1.32-2.66)
<i>Adjusted hazard ratio (95% CI) for ESRD^a</i>		
Wan, et al. ²⁴	1.15 (0.84-1.58)	4.15 (1.70-10.11)
Chi et al. ²⁵	1.13 (0.84-1.52)	2.94 (1.71-5.07)

Source: Wan et al.²⁴ and Chi et al.²⁵

Adjusted for age, sex, cardiovascular disease, diabetes mellitus, hyperlipidemia, hypertension, body mass index, and use of nonsteroidal anti-inflammatory drugs.

erythrocyte sedimentation rate.²³ There have been reports of T cell activation and the production of cytokines associated with inflammation, such as tumor necrosis factor, which have been linked to an increased risk of CV events.²³

Association Between Psoriasis and Kidney Disease

The prevalence of chronic kidney disease (CKD) in patients with psoriasis is high, with an increased risk of between 1.28 and 1.9,²⁴ depending on the study. In this setting, kidney disease develops more often in patients with more extensive skin lesions, and severe psoriasis is an independent risk factor after adjustment for the use of nephrotoxic drugs, such as NSAIDs and immunosuppressants, and other classic factors, including age and sex.²⁵

The association appears to depend on the inflammatory state characteristic of psoriasis.²⁶ Most of the studies have found an association between psoriasis and CKD only in patients with more severe forms of psoriasis (Table 1).²⁷ Psoriatic arthritis increases the risk of CKD and even of end-stage renal disease, for which a relative risk of 2.97 has been reported, compared with the healthy population.²⁵

The causes of kidney disease in patients with psoriasis are multiple. First, the kidney is a target organ for classic CV risk factors. Second, autoimmune disorders can cause glomerular impairment. Third, some of the drugs used to control psoriasis are nephrotoxic.

CKD is defined as a decrease in kidney function, represented by a glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m² or as the presence of kidney injury for at least 3 months.²⁸ Kidney injury is defined as any anatomical alteration of the organ or the presence of proteinuria or hematuria. Kidney injury can therefore be diagnosed using direct methods (histologic abnormalities on renal biopsy) or by way of markers (albuminuria or proteinuria) or abnormalities in urinary sediment or on imaging studies.

Pathological albuminuria is much more common in patients with psoriasis than in controls, and the parameters that define the severity of psoriasis correlate significantly with 24-hour albuminuria.²⁹

The Kidney as a Target of Cardiovascular Risk Factors in Psoriasis

CKD is closely related to the aging of the population and the high prevalence of diabetes and hypertension.³⁰ Onset of kidney disease is directly related to risk factors that are highly prevalent in patients with psoriasis, such as hypertension, diabetes, obesity, dyslipidemia, and metabolic syndrome, all of which are also independent CV risk factors.³¹ Therefore, any of these abnormalities can develop and contribute to the progression of kidney disease.³²

Since all these conditions are independent risk factors for CKD, risk is further increased by the presence of more than one of them. It is not surprising, therefore, that patients with psoriasis, who may have several of these conditions, are more likely to develop CKD. Hypertension, whether systolic or diastolic, is an independent predictor of kidney disease.³³ Diabetes is also an important risk factor for vascular disease with renal involvement. Diabetic nephropathy occurs in 25% to 40% of patients with a long history of type 1 or type 2 diabetes, and is also a CV risk factor.³⁴ Obesity and metabolic syndrome are also well known risk factors for impaired renal function.³⁵

Psoriasis and Glomerular Disease

Many isolated cases of associations between psoriasis and different types of glomerulonephritis have been reported, but few authors have studied this relationship in a comprehensive way. In a recent study, in which 4344 patients with psoriasis were followed up for 5 years, the authors reported an increased incidence of glomerulonephritis (HR, 1.50; 95% CI, 1.24-1.81), which may contribute to the impairment of renal function observed in this setting.²⁶ In that study, the risk increased with severity, being higher in patients with more severe disease and those with psoriatic arthritis. The type of glomerulonephritis most frequently reported in association with psoriasis is mesangial proliferative glomerulonephritis, with and without immunoglobulin A deposits.^{29,36} This type of glomerulonephritis is common in infectious and autoimmune diseases and—although the pathophysiologic mechanisms are poorly understood—the increased synthesis of polymeric immunoglobulin present in such diseases would appear to be a factor in its pathogenesis.³⁷

Association Between Drugs Used to Treat Psoriasis and Chronic Kidney Disease

There is lack of consensus in the literature on the relationship between CKD and psoriasis and on the role played by certain drugs used to treat psoriatic disease—CsA and methotrexate—because of the well known nephrotoxicity of both of these drugs.

The use of CsA has been linked to hypertension, kidney disease, and lymphoproliferative processes. Consequently, treatment with CsA for more than 2 years is not recommended.³⁸ Because it causes vasoconstriction of afferent arterioles, CsA can also cause acute renal failure. Renal

function improves within 5 to 7 days following cessation of treatment.³⁹

However, prolonged treatment with CsA may cause irreversible CKD. The recommended cumulative duration of treatment and the risk associated with CsA vary from case to case, but the study that originally detected kidney damage caused by treatment with CsA concluded that patients treated for more than 12 months were at increased risk for renal impairment.⁴⁰ There is evidence that the risk is not reduced by intermittent use and outcomes reported for intermittent regimens are similar to those reported for continuous treatment.⁴¹ Multiple studies in liver transplant patients have found no differences in renal function between groups receiving high and low doses of CsA and no increased association with kidney disease in patients on higher doses of the drug.⁴²

In the case of methotrexate, 90% of the drug is eliminated through the kidneys and the damage may be caused by renal precipitation or by the direct effect of the drug on renal tubules. Methotrexate toxicity depends on the blood concentrations achieved after administration. Levels greater than 10 μM at 24 h or greater than 1 μM at 48 h are associated with a high probability of nephrotoxicity, especially in older patients.⁴³ Some studies have reported methotrexate nephrotoxicity in patients with psoriasis.^{44,45} Although the doses used to treat psoriasis are low and few cases have been reported, dermatologists should be aware that nephrotoxic doses may be reached because the threshold varies a great deal from patient to patient.

The use of nonsteroidal anti-inflammatory drugs has been linked to increased kidney damage in patients with moderate to severe psoriasis (relative risk, 1.69).²⁶ In many cases, nonsteroidal anti-inflammatory agents are used in combination with methotrexate, a practice that could increase the risk of kidney damage.

The literature on biologic drugs includes multiple cases of autoimmune kidney disease caused by biologic therapy in patients with various diseases, including psoriasis.⁴⁶⁻⁵³ In most of these cases, the patients had membranous glomerulonephritis, although granulomatous nephritis has also been reported. These cases can be categorized as follows: glomerulonephritis associated with systemic vasculitis, glomerulonephritis in lupus-like syndromes, and isolated autoimmune renal disorders. Most of the cases reported are associated with tumor necrosis factor inhibitors.⁵⁴ Notwithstanding these findings and given their lack of end-organ toxicity, biologic agents can be a good therapeutic option in patients with CKD and even end-stage renal disease. Cases have been reported of successful treatment of psoriasis with biologic drugs in patients on hemodialysis.⁵⁵

Systemic Implications of Kidney Disease in Patients with Psoriasis

Chronic Kidney Disease as a Cardiovascular Risk Factor

CKD is a major public health problem affecting 10% of the adult population and more than 20% of people over 60 years of age.⁵⁶ Moreover, it is well known that the disease is underdiagnosed. CKD is an independent risk factor for CV disease,

and the risk of CV mortality in patients with CKD is greater than the risk of progression to dialysis or transplant.⁵⁷ CV disease associated with CKD is treatable and potentially preventable.⁵⁷

It is important to be aware of the association between impaired renal function, the onset of CV disease, and death. In clinical practice, renal function should be monitored in patients in the at-risk population, who should also be routinely tested for proteinuria (albuminuria). Monitoring is essential owing to the high incidence of kidney disease in patients with psoriasis. Once a persistent elevation of albumin in the urine (microalbuminuria) is confirmed, CV risk exists even when renal function is normal. The risk increases as renal function deteriorates. In patients with end-stage renal disease, the risk of CV disease is 20 to 30 times that of the general population.⁵⁸

The severity of renal impairment is assessed by measuring the GFR and by the presence of microalbuminuria (30-300 mg/24 h) or macroalbuminuria (> 300 mg/24 h). A GFR estimated at below 60 mL/min is defined as kidney failure and represents a significant increase in CV risk. A low GFR is often accompanied by albuminuria, and the effect of the two factors is additive. It is important to monitor and control risk factors in patients with renal impairment from the outset. Patients with renal impairment and ischemic heart disease and/or heart failure often do not receive all the treatment they should; in such cases, special attention should be paid to improving survival.⁵⁹

Assessing Emerging Cardiovascular Risk Factors

In patients with renal failure, the kidneys gradually lose the ability to excrete phosphorus. This deficit is compensated by phosphaturic mechanisms that boost the urinary excretion of phosphorus, such as increases in parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23), which maintain the normal phosphaturic capacity. The role of FGF23, a phosphatonin with 251 amino acids, is to maintain normal phosphorus levels in the body. It does this by downregulating the activity of the type II sodium/phosphate cotransporters in the proximal tubule, thereby decreasing renal tubular phosphate reabsorption. However, it also inhibits the activity of 1 α hydroxylase, thereby reducing synthesis of 1-25 dihydroxycholecalciferol from its precursor calcidiol, and increases 24 α hydroxylase, which in turn increases vitamin D catabolism. Thus, vitamin D is decreased in patients with kidney failure.⁶⁰ The increases in PTH and FGF23, together with the decrease in vitamin D, increases CV risk.⁶¹

Patients with psoriasis have decreased vitamin D levels and increased PTH levels. In winter, the prevalence of vitamin D deficiency can reach as high as 80% in patients with psoriasis.⁶² While the origin of vitamin D deficiency in psoriasis has not been studied in depth, it may have multiple implications. First, vitamin D deficiency can cause osteoporosis, reduce the patient's immune response, or increase CV mortality and the risk of diabetes.^{63,64} Vitamin D deficiency also has important implications in the pathogenesis of psoriasis because certain vitamin D receptors are responsible for the growth and differentiation of keratinocytes and for the immune functions of T cells and dendritic cells.⁶⁵ In fact, topical vitamin D derivatives have been used to

Table 2 Recommendations for Preventing Renal Damage in Patients with Psoriasis.

1. *Assess kidney function in patients in whom 3% or more of the body surface area is affected and monitor annually in patients with moderate to severe disease.*
Blood creatinine
Glomerular filtration rate calculated using formulas (MDRD-4 or CKD-EPI)
Urine albumin levels (moderate increases in albuminuria)
2. *If potentially nephrotoxic drugs are prescribed, closer monitoring of renal function is required.*
3. *If a decrease in glomerular filtration rate or a moderate increase in albuminuria is observed, the patient should be assessed by a kidney specialist.*
4. *Monitor classic cardiovascular risk factors: hypertension, diabetes, dyslipidemia, and excess weight or obesity.*

Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; MDRD 4, Modification of Diet in Renal Disease-4.

treat psoriasis and it is also possible that an increase in endogenous vitamin D production may be one of the mechanisms of action of phototherapy in this setting.^{66,67} Increased serum PTH has also been observed in patients with psoriasis and this may have direct implications on CV risk in these patients.⁶⁸ While it may be the result of vitamin D deficiency, increased PTH could also be a phosphaturic mechanism triggered by the decreased renal elimination of phosphorus.

Recommendations for Dermatologists on Prevention. What, When and How?

Psoriasis is an inflammatory disease that often has systemic effects and is associated with several CV risk factors. It would, therefore, seem wise to take all these possibilities into account when treating these patients (Table 2).

Kidney Function Testing

At least in patients with moderate to severe forms of psoriasis, as in other inflammatory disorders, kidney function should be assessed at least once a year, including measurement of microalbuminuria, creatinine, and GFR (estimated using formulas). The most commonly used formulas are those taken from the Modification of Diet in Renal Disease (MDRD) study, known as MDRD-4,⁶⁹ and those devised by the Chronic Kidney Disease Epidemiology Collaboration, known as CKD-EPI.⁷⁰ Some authors recommend testing urine albumin levels (microalbuminuria), creatinine, and estimating GFR in any patient who has plaque psoriasis affecting more than 3% of the body surface and taking particular care if the patient is on nephrotoxic drugs, such as methotrexate or CsA, irrespective of the underlying disease.²⁰ Even closer monitoring of renal function is needed when the patient is taking potentially nephrotoxic drugs.¹⁵ Nephrotoxic drugs are contraindicated in patients with kidney injury. Treatment with drugs such as CsA should never exceed 2 years. Prescribing treatments that are not nephrotoxic may be a reasonable alternative to reduce this risk.

Table 3 Psoriasis and Kidney Disease: Key Messages.

- Psoriasis is a systemic inflammatory disease that may increase the risk of comorbid diseases, such as hypertension, dyslipidemia, and diabetes.
- The risk of kidney disease is increased in patients with psoriasis and particularly in patients with more severe disease.
- Psoriasis is associated with a higher risk of mesangial proliferative glomerulonephritis.
- The increased prevalence of kidney damage in psoriasis may be the result of vascular damage caused by inflammation and other comorbidities.
- When used for long periods, some of the drugs used to treat psoriasis are nephrotoxic.
- In patients with moderate to severe psoriasis or psoriatic arthritis, renal function should be monitored regularly by measuring the glomerular filtration rate.

When monitoring detects a decrease in GFR or a higher value for microalbuminuria compared to prior measurements, the patient should be carefully assessed, if necessary by a nephrologist. We must not forget that psoriasis is a chronic disease and that early diagnosis of renal impairment will facilitate prompt stabilization of the condition, which is important since the damage is irreversible.

Cardiovascular Risk Assessment

To prevent CV events, it is essential to monitor the classic CV risk factors (hypertension, diabetes, dyslipidemia, and excess weight/obesity) in patients with psoriasis, especially those with moderate to severe disease. Patients with extensive psoriasis and those who have extracutaneous symptoms, such as arthritis, have a higher risk of comorbid disease.

The key messages of this study are shown in Table 3.

Funding

Abbvie organized and financed the face-to-face meetings of this working group.

Conflicts of Interest

Abbvie facilitated the meetings of the workgroup, but none of the company's employees participated in the collection of scientific evidence, group discussions, or drafting the article.

Raquel Rivera has received honoraria for consultancy work from Abbvie, Janssen, Lilly, and Pfizer, has served as a rapporteur for MSD, Abbvie, Janssen, Leo Pharma, Novartis and Pfizer and as a researcher for Abbvie, Pfizer, Janssen, Celgene, Lilly, Novartis, Leo Pharma, and has received funding to attend conferences from Abbvie, Janssen, Novartis, Pfizer, Leo Pharma, Celgene and MSD

References

1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. *J Invest Dermatol.* 2013;133:377–85.

2. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. *Lancet*. 2007;370:263–71.
3. Ferrándiz C, Carrascosa JM, Toro M. Prevalencia de la psoriasis en España en la era de los agentes biológicos. *Actas Dermosifiliogr*. 2014;105:504–9.
4. García-Díez A, Foraster CF, Sebastián FV, Tudela LL, Llach XB, Fernández GS. What characterizes the severity of psoriasis? Results from an epidemiological study of over 3,300 patients in the Iberian region. *Dermatology*. 2008;216:137–51.
5. Tsai TF, Wang TS, Hung ST, Tsai PI, Schenkel B, Zhang M, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. *J Dermatol Sci*. 2011;63:40–6.
6. Daudén E, Castañeda S, Suárez C, García Campayo J, Blasco AJ, Aguilar MD, et al. Abordaje integral de la comorbilidad del paciente con psoriasis. *Actas Dermosifiliogr*. 2012;103 Supl 1:1–64.
7. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' health study II. *Arch Intern Med*. 2007;167:1670–5.
8. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. *J Am Acad Dermatol*. 2006;55:829–35.
9. Lee M-S, Lin R-Y, Lai M-S. Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: A nationwide population-based cohort study. *J Am Acad Dermatol*. 2014;70:691–8.
10. Boehncke W-H, Boehncke S, Tobin A-M, Kirby B. The 'psoriatic march': A concept of how severe psoriasis may drive cardiovascular comorbidity. *Exp Dermatol*. 2011;20:303–7.
11. Nijsten T, Wakkee M. Complexity of the association between psoriasis and comorbidities. *J Invest Dermatol*. 2009;129:1601–3.
12. Ciclosporina. Ficha técnica [cited 8 Feb 2016]. Available from: http://www.aemps.gob.es/cima/pdfs/es/ft/70992/70992_ft.pdf
13. Acitretina. Ficha técnica [cited 8 Feb 2016]. Available from: http://www.aemps.gob.es/cima/pdfs/es/ft/74726/74726_ft.pdf
14. Stern RS, Nijsten T. Going beyond associative studies of psoriasis and cardiovascular disease. *J Invest Dermatol*. 2012;132:499–501.
15. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. *JAMA*. 2006;296:1735–41.
16. Dowlathshahi EA, Kavousi M, Nijsten T, Ikram MA, Hofman A, Franco OH, et al. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: The Rotterdam Study. *J Invest Dermatol*. 2013;133:2347–54.
17. Coban M, Tasli L, Turgut S, Özkan S, Tuñç Ata M, Akın F. Association of adipokines, insulin resistance, hypertension and dyslipidemia in patients with psoriasis vulgaris. *Ann Dermatol*. 2016;28:74–9.
18. Khovichunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: Mechanisms and consequences to the host. *J Lipid Res*. 2004;45:1169–96.
19. Gottlieb AB, Dann F. Comorbidities in patients with psoriasis. *Am J Med*. 2009;122:1150, e1–9.
20. Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, et al. Prevalence of metabolic syndrome in patients with psoriasis: A population-based study in the United Kingdom. *J Invest Dermatol*. 2012;132:556–62.
21. Tobin AM, Veale DJ, Fitzgerald O, Rogers S, Collins P, O'Shea D, et al. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. *J Rheumatol*. 2010;37:1386–94.
22. Parisi R, Rutter MK, Lunt M, Young HS, Symmons DP, Griffiths CE, et al. Psoriasis and the risk of major cardiovascular events: Cohort study using the clinical practice research datalink. *J Invest Dermatol*. 2015;135:2189–97.
23. John H, Kitas G. Inflammatory arthritis as a novel risk factor for cardiovascular disease. *Eur J Intern Med*. 2012;23:575–9.
24. Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM. Risk of moderate to advanced kidney disease in patients with psoriasis: Population based cohort study. *BMJ*. 2013;347:f5961.
25. Chi CC, Wang J, Chen YF, Wang SH, Chen FL, Tung TH. Risk of incident chronic kidney disease and end-stage renal disease in patients with psoriasis: A nationwide population-based cohort study. *J Dermatol Sci*. 2015;78:232–8.
26. Chiu HY, Huang HL, Li CH, Yin YJ, Chen HA, Hsu ST, et al. Increased risk of glomerulonephritis and chronic kidney disease in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. *Br J Dermatol*. 2015;173:146–54.
27. Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: A population-based study. *Br J Dermatol*. 2011;165:1037–43.
28. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int (Suppl)*. 2013;3:1–150.
29. Dervisoglu E, Akturk AS, Yildiz K, Kiran R, Yilmaz A. The spectrum of renal abnormalities in patients with psoriasis. *Int Urol Nephrol*. 2012;44:509–14.
30. Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the US general population: The NHANES III study. *Mayo Clin Proc*. 2005;80:1270–7.
31. Fox C, Larson MG, Leip EP, Culleton B, Wilson PWF, Levy D. Predictors of new-onset kidney disease in a community-based population. *JAMA*. 2004;291:844–50.
32. Sarafidis P, Whaley-Connell A, Sowers JR, Bakris GL. Cardiometabolic syndrome and chronic kidney disease: What is the link? *J Cardiometabol Syndr*. 2006;1:58–65.
33. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al., SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med*. 2015;373:2103–16.
34. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and chronic kidney disease: 2012 update. *Am J Kidney Dis*. 2012;60:850–86.
35. Praga M, Hernández E, Herrero JC, Morales E, Revilla Y, Díaz-González R, et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. *Kidney Int*. 2000;58:2111–8.
36. Jiao Y, Xu H, Li H, Li X. Mesangial proliferative glomerulonephritis with or without IgA deposits: The morphological characters in psoriasis vulgaris. *Nephron Clin Pract*. 2008;108:c221–5.
37. Pouria S, Barratt J. Secondary IgA nephropathy. *Semin Nephrol*. 2008;28:27–37.
38. Griffiths CE, Dubertret L, Ellis CN, Finlay AY, Finzi AF, Ho VC, et al. Ciclosporin in psoriasis clinical practice: An international consensus statement. *Br J Dermatol*. 2004;150 Suppl 67:11–23.
39. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy. *Kidney Int*. 1996;50:1089–100.
40. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. *N Engl J Med*. 1984;311:699–705.
41. Maza A, Montaudié H, Sbidian E, Gallini A, Aractingi S, Aubin F, et al. Oral cyclosporin in psoriasis: A systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. *J Eur Acad Dermatol Venereol*. 2011;25 Suppl 2:19–27.
42. Issa N, Kukla A, Ibrahim HN. Calcineurin inhibitor nephrotoxicity: A review and perspective of the evidence. *Am J Nephrol*. 2013;37:602–12.

43. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. *Oncologist*. 2006;11:694–703.
44. Jariwala P, Kumar V, Kothari K, Thakkar S, Umrigar DD. Acute methotrexate toxicity: A fatal condition in two cases of psoriasis. *Case Rep Dermatol Med*. 2014;2014:946716.
45. Maejima H, Watarai A, Nakano T, Katayama C, Nishiyama H, Katsuoka K. Adverse effects of methotrexate in three psoriatic arthritis patients. *Rheumatol Int*. 2014;34:571–4.
46. Korsten P, Sweiss NJ, Nagorsnik U, Niewold TB, Gröne HJ, Gross O, et al. Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab. *Am J Kidney Dis*. 2010;56:e17–21.
47. Gupta A, Pandyala P, Arora P, Sitrin MD. Development of the nephrotic syndrome during treatment of Crohn's disease with adalimumab. *J Clin Gastroenterol*. 2011;45:e30–3.
48. Kaushik P, Rahmani M, Ellison W. Membranous glomerulonephritis with the use of etanercept in ankylosing spondylitis. *Ann Pharmacother*. 2011;45:e62.
49. Wei SS, Sinniah R. Adalimumab (TNF α inhibitor) therapy exacerbates IgA glomerulonephritis acute renal injury and induces lupus autoantibodies in a psoriasis patient. *Case Rep Nephrol*. 2013;2013:812781.
50. Yoshioka T, Yamakawa T, Yamaguchi M, Nomura R. Granulomatous interstitial nephritis in a patient with Behçet's disease treated with infliximab. *Nihon Jinzo Gakkai Shi*. 2013;55:1412–7, abstract only [Article in Japanese].
51. Yahya TM, Dhanyamraju S, Harrington TM, Prichard JW. Spontaneous resolution of lupus nephritis following withdrawal of etanercept. *Ann Clin Lab Sci*. 2013;43:447–8.
52. Akiyama M, Kaneko Y, Hanaoka H, Kuwana M, Takeuchi T. Acute kidney injury due to renal sarcoidosis during etanercept therapy: A case report and literature review. *Intern Med*. 2015;54:1131–4.
53. Kluger N. Psoriasis-associated IgA nephropathy under infliximab therapy. *Int J Dermatol*. 2015;54:e79–93.
54. Piga M, Chessa E, Ibba V, Mura V, Floris A, Cauli A, et al. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: Systematic literature review and analysis of a monocentric cohort. *Autoimmun Rev*. 2014;13:873–9.
55. Kusakari Y, Yamasaki K, Takahashi T, Tsuchiyama K, Shimada-Omori R, Nasu-Tamabuchi M, et al. Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: A case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure. *J Dermatol*. 2015;42:727–30.
56. Otero A, de Francisco A, Gayoso P, García F, EPIRCE Study Group. Prevalence of chronic renal disease in Spain: Results of the EPIRCE study. *Nefrologia*. 2010;30:78–86.
57. Alcázar R, Egocheaga MI, Orte L, Lobos JM, González Parra E, Alvarez Guisasaola F, et al. SEN-SEMFYC consensus document on chronic kidney disease. *Nefrologia*. 2008;28:273–82.
58. Berl T, Henrich W. Kidney-heart interactions: Epidemiology, pathogenesis, and treatment. *Clin J Am Soc Nephrol*. 2006;1:8–18.
59. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, et al. The association among renal insufficiency, pharmacotherapy and outcomes in 6247 patients with heart failure and coronary artery disease. *J Am Coll Cardiol*. 2004;44:1587–92.
60. Gonzalez-Parra E, Tuñón J, Egido J, Ortiz A. Phosphate: A stealthier killer than previously thought. *Cardiovasc Pathol*. 2012;21:372–81.
61. Tuñón J, Cristóbal C, Tarín N, Aceña Á, González-Casaus ML, Huelmos A, et al. Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease. *PLoS One*. 2014;9:e95402.
62. Gisondi P, Rossini M, di Cesare A, Idolazzi L, Farina S, Beltrami G, et al. Vitamin D status in patients with chronic plaque psoriasis. *Br J Dermatol*. 2012;166:505–10.
63. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: A prospective study. *Arch Intern Med*. 2008;168:1174–8.
64. González-Parra E, Egido J. Vitamin D, metabolic syndrome and diabetes mellitus. *Med Clin (Barc)*. 2014;142:493–6.
65. Tang L, Yu Y, Chen J, Li Q, Yan M, Guo Z. The inhibitory effect of VitD3 on proliferation of keratinocyte cell line HACAT is mediated by down-regulation of CXCR2 expression. *Clin Exp Dermatol*. 2003;28:416–9.
66. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, American Academy of Dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. *J Am Acad Dermatol*. 2009;60:643–59.
67. Ryan C, Moran B, McKenna MJ, Murray BF, Brady J, Collins P, et al. The effect of narrowband UV-B treatment for psoriasis on vitamin D status during wintertime in Ireland. *Arch Dermatol*. 2010;146:836–42.
68. Regaña MS, Ezquerria GM, Millet PU. Serum levels of parathyroid hormone and parathyroid-related peptide in psoriasis. *Acta Derm Venereol*. 2005;85:420–3.
69. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med*. 1999;130:461–70.
70. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AFJ3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150:604–12.